LN
LNSR.US LENSAR Inc
- Market cap
- USD 61.5M
- P/E
- 11.4x
- P/B
- 5.55x
- ROE
- 423.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LNSR.US undervalued?
Graham numberLNSR.US trades 67.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LENSAR Inc fundamental analysis
No fundamental analysis for LENSAR Inc yet.
LENSAR Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, p…
Full company profileLENSAR Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LENSAR Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 24.4M | 30.5M | 26.4M | 34.5M | 35.4M | 42.2M | 53.5M | 58.4M | 58.7M |
| Gross Profit | 9.61M | 13.2M | 14.1M | 17.8M | 20.0M | 21.1M | 25.9M | 27.1M | 32.4M |
| Operating Income | -9.32M | -12.7M | -18.5M | -19.7M | -20.2M | -12.2M | -10.7M | -24.6M | 3.92M |
| EBITDA | -4.66M | -8.79M | -15.9M | -16.8M | -16.5M | -10.9M | -3.01M | -29.8M | 47.5M |
| Net Income | -12.6M | -14.7M | -19.8M | -19.6M | -19.9M | -14.4M | -31.4M | -34.3M | 46.9M |
| EPS | -12 | -1.38 | -1.81 | -2.09 | -1.96 | -1.31 | -2.73 | -2.87 | 3.78 |
| Balance Sheet | |||||||||
| Total Assets | 28.9M | 34.5M | 79.1M | 66.5M | 55.8M | 69.6M | 66.3M | 71.4M | 67.1M |
| Total Liabilities | 49.4M | 65.1M | 11.9M | 11.6M | 13.9M | 22.4M | 47.7M | 97.4M | 42.2M |
| Shareholders' Equity | -20.5M | -30.6M | 67.2M | 54.9M | 42.0M | 47.2M | 18.6M | -26.0M | 11.1M |
| Cash & Short-term Investments | 3.34M | 4.62M | 40.6M | 31.6M | 14.7M | 24.1M | 22.5M | 18.0M | 12.6M |
| Total Debt | 41.2M | 20.5M | 3.81M | 3.32M | 2.80M | 2.31M | 2.61M | 2.74M | 2.19M |
| Cash Flow | |||||||||
| Operating Cash Flow | -1.89M | -12.6M | -13.8M | -8.97M | -14.9M | -9.66M | -2.28M | -14.8M | -7.02M |
| Capital Expenditure | 3.25M | 2.09M | 366K | 354K | 115K | 236K | 156K | 83.0K | 196K |
| Free Cash Flow | -5.13M | -14.7M | -14.2M | -9.32M | -15.0M | -9.90M | -2.43M | -14.9M | -7.21M |
| Ratios | |||||||||
| ROE | - | - | -29.4% | -35.7% | -47.4% | -30.5% | -168.4% | - | 423.4% |
| ROA | -43.6% | -42.4% | -25.0% | -29.5% | -35.7% | -20.7% | -47.4% | -48.0% | 69.9% |
| Net Profit Margin | -51.6% | -48.0% | -75.0% | -56.9% | -56.3% | -34.1% | -58.7% | -58.7% | 79.8% |
| Debt to Equity | - | - | 0.06x | 0.06x | 0.07x | 0.05x | 0.14x | - | 0.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
LENSAR Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 1.86M | 0.17 | - |
| 2019 | USD 31.0K | 0.00 | - |
| 2018 | USD 198K | 0.19 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns LENSAR Inc
- Insiders 21.58%
- Institutions 45.03%
- Public & others 33.39%
- Shares outstanding 12.3M
- Free float 8.85M
Top funds holding LNSR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Brandes Small Cap Value R6 | 714K | 5.81% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 276K | 2.24% | 0.00% | Sep 2026 |
| Stork Fund Dynamic MultiStrategies O EUR | 118K | 0.96% | +0.80% | Jun 2026 |
| Mediolanum BB Global Sm Cp Eq LA | 88.8K | 0.72% | 0.00% | Jun 2026 |
| Cigogne UCITS M&A Arbitrage C1 | 71.2K | 0.58% | +16.23% | Mar 2026 |
| Fidelity Extended Market Index | 51.4K | 0.42% | -0.38% | Sep 2026 |
| Man Event Driven Alternative IN USD | 42.7K | 0.35% | +1.06% | Jul 2026 |
| 1290 VT GAMCO Mergers & Acquisitions IB | 33.0K | 0.27% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 31.1K | 0.25% | -12.15% | Sep 2026 |
| iShares Micro-Cap ETF | 29.5K | 0.24% | 0.00% | Oct 2026 |
| Gabelli Entpr Mergers & Acquisitions Y | 24.0K | 0.20% | 0.00% | Jul 2026 |
| DFA U.S. Targeted Value I | 22.1K | 0.18% | -42.81% | Sep 2026 |
| Gabelli ABC I | 20.0K | 0.16% | 0.00% | Jun 2026 |
| Fidelity Total Market Index | 17.1K | 0.14% | 0.00% | Sep 2026 |
| GDL Fund | 15.0K | 0.12% | 0.00% | Jun 2026 |
| Fidelity Series Total Market Index | 14.4K | 0.12% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 11.1K | 0.09% | -39.67% | Sep 2026 |
| Dimensional US Small Cap ETF | 7.97K | 0.06% | 0.00% | Oct 2026 |
| Nuveen NASDAQ 100 Dynamic Overwrite | 7.86K | 0.06% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 7.15K | 0.06% | 0.00% | Sep 2026 |
Top institutions holding LNSR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Brandes Investment Partners & Co | 1.08M | 8.75% | +4.90% | Jun 2026 |
| Vanguard Capital Management, LLC | 403K | 3.28% | +3.26% | Jun 2026 |
| RBF LLC | 189K | 1.53% | +314.39% | Jun 2026 |
| BlackRock Inc | 185K | 1.51% | -70.57% | Jun 2026 |
| Css LLC | 163K | 1.33% | 0.00% | Jun 2026 |
| Kerrisdale Advisers, LLC | 139K | 1.13% | 0.00% | Jun 2026 |
| Millennium Management LLC | 121K | 0.98% | +860.45% | Jun 2026 |
| DCF Advisers, LLC | 118K | 0.96% | 0.00% | Jun 2026 |
| Evernest Financial Advisors LLC | 118K | 0.96% | +78.94% | Jun 2026 |
| Geode Capital Management, LLC | 114K | 0.93% | -50.23% | Jun 2026 |
| UBS Group AG | 85.6K | 0.70% | +2.84% | Jun 2026 |
| Yakira Capital Management, Inc. | 83.3K | 0.68% | 0.00% | Jun 2026 |
| State Street Corp | 81.0K | 0.66% | -40.34% | Jun 2026 |
| Man Group PLC | 78.0K | 0.63% | +3.87% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 72.9K | 0.59% | -51.92% | Sep 2026 |
| Deltec Asset Management LLC | 65.0K | 0.53% | 0.00% | Jun 2026 |
| Alpine Partners VI, LLC | 59.6K | 0.48% | -20.57% | Jun 2026 |
| The Goldman Sachs Group Inc | 59.5K | 0.48% | -44.31% | Jun 2026 |
| Gabelli Funds LLC | 59.0K | 0.48% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 57.8K | 0.47% | -11.92% | Jun 2026 |
LENSAR Inc company profile
- Company name
- LENSAR Inc
- Ticker
- LNSR.US
- Exchange
- USA Stocks
- Listed since
- Oct 2, 2020
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 150
- Fiscal year end
- December
- Address
- 2800 Discovery Drive, Orlando, FL, United States, 32826
- Phone
- 888 536 7271
- Website
- lensar.com
About LENSAR Inc
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
LENSAR Inc management
4- Mr. Nicholas T. CurtisPresident, CEO & Director · born 1956
- Mr. Alan B. ConnaughtonChief Operating Officer · born 1972
- Mr. Michael A. RossiInterim CFO & Principal Financial Officer and Secretary · born 1974
- Ms. Kendra W. WongPrincipal Accounting Officer · born 1980